AstraZeneca

Company Snapshot

Founded: 1999
Entity Type: Public
Employees: 94,300
Region: The Americas
Revenue: $54,073.0 Millions
Revenue Year: 2024
Segment: Oncology
Headquarter: Cambridge, U.K.
Key Geographics: The Americas, U.K., Rest of Europe, Asia, Africa, Australasia
Corporate Address: 1 Francis Crick Avenue Cambridge Biomedical Campus Cambridge CB2 0AA, U.K. Tel: +44-(0)20-3749-5000 Web: www.astrazeneca.com

Company Overview

AstraZeneca is a U.K.-based biopharmaceutical company. The company operates in three segments and is focused on our chosen therapy areas: Oncology, Biopharmaceuticals, and rare diseases. The Biopharmaceuticals segment comprises therapeutic areas, including cardiovascular, renal, and metabolism (CVRM), respiratory and immunology (R&I), and vaccines and immune therapies (V&I). The company’s products are sold in over 125 countries.

The company’s R&D focuses on bispecific, inhaled fragments, ADCs, and cell-depleting monoclonal antibodies in antibody therapeutics.

The major brands are Forxiga or Farxiga, Ebymect, Edistride, Xigduo, Bydureon, Lynparza, Bydureon, Xigduo, Edistride, and Ebymect.

Financial Highlights (FY 2024)

Net Revenue: ***
Total Current Liabilities: ***
Total Current Assets: ***
R&D expenses: ***
Operating Income: ***

This information is available for BCC Research members only.

AstraZeneca In Reports

Biological Therapies for Cancer: Technologies and Global Markets

According to our research analyst biological therapies for cancer market includes global revenue ($ Million) for the base year data of 2024 and estimated data for the forecast period 2025 through 2030.

Fusion Proteins: Global Market

Our detailed report on the fusion protein market and analyzes trends It includes global revenue ($ Million) for the base year 2024, estimated data for 2025.

mRNA: Therapeutics and Global Markets

Our Research report provides an overview of the mRNA therapeutics market includes global revenue (in $ million) for the base year data 2024, estimated data for 2025, and forecast data from 2026 to 2030.

Company's Business Segments

  • Oncology : Cancer Care Africa, the Lung Ambition Alliance
  • Rare Disease : Hypophosphatasia (HPP), Neurofibromatosis Type 1 (NF1) Plexiform Neurofibromas (PN), Wilson disease, and Rare cancers.
  • Other Medicines : Cardiovascular (CV), Renal & Metabolism, Respiratory & Immunology, and Vaccines & Immune Therapies.

Applications/End User Industries

  • Oncology
  • Cardiovascular
  • Renal
  • Metabolism
  • Respiratory and Immunology (R&I)
  • Vaccines and Immune Therapies (V&I)
  • Rare Disease
AI Sentiment